More on Quest Diagnostics (DGX) Q2: Sells rights to royalties of "non-core" experimental cancer...

|About: Quest Diagnostics Incorpo... (DGX)|By:, SA News Editor

More on Quest Diagnostics (DGX) Q2: Sells rights to royalties of "non-core" experimental cancer drug Ibrutinib to Royalty Pharma for $485M, with resulting cash proceeds $300M. Ibrutinib is developed by Pharmacyclics (PCYC) and Johnson & Johnson (JNJ). (PR)